| Name | Title | Contact Details |
|---|
Bionova Medical is a privately held medical device company in Germantown, TN. Bionova, founded in 2011, is committed to providing advanced treatment options to practicing physicians.
Bio-Path is a biotechnology company developing targeted therapies for acute myeloid leukemia (AML), chronic myeloid leukemia (CML) and other challenging cancers. The company`s lead product candidate, prexigebersen (Liposomal Grb2 Antisense), formerly BP1001, is currently being assessed in a Phase 2 clinical study in 54 people with previously untreated AML who are not eligible for or who have decided to forego intensive induction therapy because of their age or fragile health.
Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development. In addition, we have leveraged our earlier stage drug discovery and development capabilities to establish multiple partnerships and collaborations with leading pharmaceutical and biopharmaceutical partners. These alliances are designed to advance the development of multiple Exelixis-discovered therapies, and allow Exelixis to focus on maximizing the potential of cabozantinib. Exelixis has worldwide rights to cabozantinib, which we believe could have the potential to treat a wide variety of cancers. Cabozantinib received its initial regulatory approval for a single indication in 2012, and is marketed for that indication under the trade name COMETRIQ®. Cabozantinib is also the subject of a broad, global clinical development program that includes approximately 45 ongoing or planned clinical trials. Exelixis is the sponsor of two active global, randomized phase 3 pivotal trials: the METEOR trial in metastatic renal cell carcinoma, for which positive top-line results were announced in July 2015, and the CELESTIAL trial in advanced hepatocellular carcinoma. Founded and incorporated in 1994, Exelixis is headquartered in South San Francisco, California. We are committed to excellence in all aspects of our business and are dedicated to improving the care of, and outcomes for, patients with cancer.
Priovant Therapeutics is a clinical stage biotechnology company developing targeted therapies for patients with severe autoimmune disease.
Gevo has a mission to transform renewable energy into low carbon transportation fuels. This next generation of renewable premium gasoline, jet fuel and diesel fuel with the potential to achieve zero carbon emissions, addressing the market need of reducing greenhouse gas emissions with sustainable alternatives. Gevo uses low-carbon renewable resource-based carbohydrates as raw materials and is in an advanced state of developing renewable electricity and renewable natural gas for use in production processes, resulting in low-carbon fuels with substantially reduced carbon intensity (the level of greenhouse gas emissions compared to standard petroleum fossil-based fuels across their lifecycle). Gevo`s products perform as well or better than traditional fossil-based fuels in infrastructure and engines, but with substantially reduced greenhouse gas emissions. In addition to addressing the problems of fuels, Gevo`s technology also enables certain plastics, such as polyester, to be made with more sustainable ingredients. Gevo`s ability to penetrate the growing low-carbon fuels market depends on the price of oil and the value of abating carbon emissions that would otherwise increase greenhouse gas emissions. Gevo believes that its proven, patented, technology enabling the use of a variety of low-carbon sustainable feedstocks to produce price-competitive low carbon products such as gasoline components, jet fuel, and diesel fuel yields the potential to generate project and corporate returns that justify the build-out of a multi-billion-dollar business.